Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Bioanalytical Systems, Inc is a diagnostics & research business based in the US. Bioanalytical Systems shares (BASI) are listed on the NASDAQ and all prices are listed in US Dollars. Bioanalytical Systems employs 397 staff and has a trailing 12-month revenue of around USD$60.5 million.
|Latest market close||USD$8.53|
|52-week range||USD$3.05 - USD$10.74|
|50-day moving average||USD$7.0845|
|200-day moving average||USD$5.5319|
|Wall St. target price||USD$17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.124|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-34.23%|
|1 month (2020-12-16)||7.03%|
|3 months (2020-10-15)||66.60%|
|6 months (2020-07-15)||81.49%|
|1 year (2020-01-15)||56.51%|
|2 years (2019-01-15)||556.15%|
|3 years (2018-01-12)||255.42%|
|5 years (2016-01-15)||527.21%|
Valuing Bioanalytical Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioanalytical Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bioanalytical Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.2 million.
The EBITDA is a measure of a Bioanalytical Systems's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$60.5 million|
|Gross profit TTM||USD$18.2 million|
|Return on assets TTM||-2.25%|
|Return on equity TTM||-51.19%|
|Market capitalisation||USD$105.7 million|
TTM: trailing 12 months
There are currently 10,597 Bioanalytical Systems shares held short by investors – that's known as Bioanalytical Systems's "short interest". This figure is 117.7% up from 4,868 last month.
There are a few different ways that this level of interest in shorting Bioanalytical Systems shares can be evaluated.
Bioanalytical Systems's "short interest ratio" (SIR) is the quantity of Bioanalytical Systems shares currently shorted divided by the average quantity of Bioanalytical Systems shares traded daily (recently around 36541.379310345). Bioanalytical Systems's SIR currently stands at 0.29. In other words for every 100,000 Bioanalytical Systems shares traded daily on the market, roughly 290 shares are currently held short.
However Bioanalytical Systems's short interest can also be evaluated against the total number of Bioanalytical Systems shares, or, against the total number of tradable Bioanalytical Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bioanalytical Systems's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Bioanalytical Systems shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable Bioanalytical Systems shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bioanalytical Systems.
Find out more about how you can short Bioanalytical Systems stock.
We're not expecting Bioanalytical Systems to pay a dividend over the next 12 months.
Over the last 12 months, Bioanalytical Systems's shares have ranged in value from as little as $3.05 up to $10.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bioanalytical Systems's is 1.7638. This would suggest that Bioanalytical Systems's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bioanalytical Systems, Inc., doing business as Inotiv, a pharmaceutical development company, provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical toxicology and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.